A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)

NCT03685500 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

78

Enrollment

OTHER

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Symtuza® (TAF/FTC/DRV/c)
DRUG: ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)

Sponsor

Fundacion SEIMC-GESIDA

Collaborators

[object Object]